Equities analysts expect Orgenesis Inc. (NYSE:ORGS) to post sales of $7.78 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Orgenesis’ earnings. The lowest sales estimate is $7.56 million and the highest is $8.00 million. The firm is expected to report its next earnings results on Wednesday, February 27th.
According to Zacks, analysts expect that Orgenesis will report full-year sales of $20.63 million for the current year, with estimates ranging from $20.41 million to $20.85 million. For the next fiscal year, analysts forecast that the firm will post sales of $39.08 million, with estimates ranging from $32.66 million to $45.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Orgenesis.
Separately, Dawson James reissued a “buy” rating on shares of Orgenesis in a research report on Thursday, December 20th.
Orgenesis Inc, a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business.
Further Reading: How to interpret a stock’s beta number
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.